Toward Greater Insights on Pharmacokinetics and Exposure–Response Relationships for Therapeutic Biologics in Oncology Drug Development

Citations Over TimeTop 10% of 2017 papers

Abstract

There has been increased interest in optimizing dosing regimens for oncology products over the past decade. Investigations to refine dosing regimens often occur after new drug approval. There is growing focus on the use of exposure-response (ER) approaches to identify optimal dosing regimens for therapeutic biologics. Herein, we describe several recent observations that have informed our thinking on the use of ER analyses in the dose regimen optimization of therapeutic biologics developed to treat cancer.

Related Papers

• → Sensitivity and specificity of dosing alerts for dosing errors among hospitalized pediatric patients(2014)29 cited
• → Efficacy of nivolumab four-weekly dosing schedule based on body weight(2019)10 cited
• → Impact of phosphate binders on medication dosing frequency, timing, and number of prescribed pills in hemodialysis patients(2022)2 cited
• → The Impact of Role of Pharmacists in Renal Dosage Adjustment Program on Renal Drug Dosing Errors: A Quasi-Experimental Study(2021)1 cited
• → Pharmacokinetics‐Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease(2019)1 cited